Possible Role of Cyclic AMP Response Element Binding/Brain-Derived Neurotrophic Factor Signaling Pathway in Mediating the Pharmacological Effects of Duloxetine Against Methamphetamine Use-Induced Cognitive Impairment and Withdrawal-Induced Anxiety...

Overview

Journal Adv Biomed Res

Specialty Biomedical Engineering

Date 2019 Apr 18

PMID 30993081

Citations 9

Authors

Sanaz Ramezany Yasuj

Mona Nourhashemi

Saghar Keshavarzi

Majid Motaghinejad

Manijeh Motevalian

Affiliations

Soon will be listed here.

Abstract

Background: Duloxetine is used for treating depression and anxiety. The current study evaluated the effects of duloxetine against methamphetamine withdrawal-induced anxiety, depression, and motor disturbances and methamphetamine use-induced cognitive impairments.

Materials And Methods: Ninety-six adult male rats were used for two independent experiments. Each experiment consisted of Groups 1 and 2 which received normal saline (0.2 ml/rat) and methamphetamine (10 mg/kg) respectively, Groups 3, 4, and 5 received both methamphetamine and duloxetine at doses of 5, 10, and 15 mg/kg, respectively. Groups 6, 7, and 8 received 5, 10, and 15 mg/kg of duloxetine, respectively. All administrations were performed for 21 days. In experiment 1, elevated plus maze (EPM), open-field test (OFT), forced swim test (FST), and tail suspension test (TST) were used to examine anxiety and depression in animals during withdrawal period. In experiment 2, Morris water maze (MWM) test was used to assess the effect of methamphetamine use followed by duloxetine treatment, on learning and memory. In the experiments, the expression of cyclic AMP response element binding (CREB) and brain-derived neurotrophic factor (BDNF) proteins were evaluated using enzyme-linked immunosorbent assay.

Results: In the first experiment, duloxetine at all doses attenuated methamphetamine withdrawal induced-depression, anxiety, and motor disturbances in FST, OFT, EPM, and TST. In the second experiment, duloxetine at all doses attenuated methamphetamine use-induced cognitive impairment in MWM. In both experiments, duloxetine activated cAMP, CREB, and BDNF proteins' expression in methamphetamine-treated rats.

Conclusions: Duloxetine can protect the brain against methamphetamine withdrawal-induced mood and motor disturbances and can also inhibit methamphetamine-induced cognitive impairment, possibly via cAMP/CREB/BDNF signaling pathway.

Citing Articles

Revealing the Mechanism of Baroni in Depression Treatment Through Integrated Network Pharmacology and Transcriptomic Analysis.

Gao S, Lu J, Gu Y, Zhang Y, Wang C, Gao F Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770546 PMC: 11677347. DOI: 10.3390/ph17121704.

Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.

Yates J Subst Abuse Rehabil. 2024; 15:125-161.

PMID: 39228432 PMC: 11370775. DOI: 10.2147/SAR.S431273.

Inflammatory Pathogenesis of Post-stroke Depression.

Feng X, Ma X, Li J, Zhou Q, Liu Y, Song J Aging Dis. 2024; .

PMID: 38377025 PMC: 11745428. DOI: 10.14336/AD.2024.0203.

GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT+HG-induced toxicity.

Ma Q, Wang L, Liu X, An Z, Luo X, Zhang L Heliyon. 2023; 9(8):e18491.

PMID: 37576283 PMC: 10412908. DOI: 10.1016/j.heliyon.2023.e18491.

Gut microbiota from sigma-1 receptor knockout mice induces depression-like behaviors and modulates the cAMP/CREB/BDNF signaling pathway.

Li J, Liu J, Li X, Liu Y, Yang J, Chen L Front Microbiol. 2023; 14:1143648.

PMID: 37089558 PMC: 10116000. DOI: 10.3389/fmicb.2023.1143648.

References

Zweben J, Cohen J, Christian D, Galloway G, Salinardi M, Parent D . Psychiatric symptoms in methamphetamine users. Am J Addict. 2004; 13(2):181-90. DOI: 10.1080/10550490490436055. View

Narita M, Aoki K, Takagi M, Yajima Y, Suzuki T . Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience. 2003; 119(3):767-75. DOI: 10.1016/s0306-4522(03)00099-x. View

Clemens K, Van Nieuwenhuyzen P, Li K, Cornish J, Hunt G, McGregor I . MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl). 2004; 173(3-4):318-25. DOI: 10.1007/s00213-004-1786-x. View

Chen G, Bower K, Ma C, Fang S, Thiele C, Luo J . Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 2004; 18(10):1162-4. DOI: 10.1096/fj.04-1551fje. View

Greer T, Sunderajan P, Grannemann B, Kurian B, Trivedi M . Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?. Depress Res Treat. 2014; 2014:627863. PMC: 3915915. DOI: 10.1155/2014/627863. View

Motaghinejad M, Fatima S, Karimian M, Ganji S . Protective effects of forced exercise against nicotine-induced anxiety, depression and cognition impairment in rat. J Basic Clin Physiol Pharmacol. 2015; 27(1):19-27. DOI: 10.1515/jbcpp-2014-0128. View

Volkow N, Chang L, Wang G, Fowler J, Franceschi D, Sedler M . Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001; 158(3):377-82. DOI: 10.1176/appi.ajp.158.3.377. View

Carlezon Jr W, Duman R, Nestler E . The many faces of CREB. Trends Neurosci. 2005; 28(8):436-45. DOI: 10.1016/j.tins.2005.06.005. View

Dugan S, Fuller M . Duloxetine: a dual reuptake inhibitor. Ann Pharmacother. 2004; 38(12):2078-85. DOI: 10.1345/aph.1E084. View

10.

Westanmo A, Gayken J, Haight R . Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm. 2005; 62(23):2481-90. DOI: 10.2146/ajhp050006. View

11.

Ji D, Gilpin N, Richardson H, Rivier C, Koob G . Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol. 2008; 19(1):1-12. PMC: 2586833. DOI: 10.1097/FBP.0b013e3282f3cf70. View

12.

Motaghinejad M, Motevalian M, Fatima S, Beiranvand T, Mozaffari S . Topiramate via NMDA, AMPA/kainate, GABA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats. J Neural Transm (Vienna). 2017; 124(11):1369-1387. DOI: 10.1007/s00702-017-1771-2. View

13.

Blendy J . The role of CREB in depression and antidepressant treatment. Biol Psychiatry. 2006; 59(12):1144-50. DOI: 10.1016/j.biopsych.2005.11.003. View

14.

Motaghinejad M, Motevalian M, Fatima S, Faraji F, Mozaffari S . The Neuroprotective Effect of Curcumin Against Nicotine-Induced Neurotoxicity is Mediated by CREB-BDNF Signaling Pathway. Neurochem Res. 2017; 42(10):2921-2932. DOI: 10.1007/s11064-017-2323-8. View

15.

Kalechstein A, Newton T, Green M . Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci. 2003; 15(2):215-20. DOI: 10.1176/jnp.15.2.215. View

16.

Siepmann T, Mueck-Weymann M, Oertel R, Kirch W, Pittrow D, Siepmann M . The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. Pharmacopsychiatry. 2008; 41(4):146-50. DOI: 10.1055/s-2008-1076724. View

17.

Thrash B, Karuppagounder S, Uthayathas S, Suppiramaniam V, Dhanasekaran M . Neurotoxic effects of methamphetamine. Neurochem Res. 2009; 35(1):171-9. DOI: 10.1007/s11064-009-0042-5. View

18.

Walf A, Frye C . The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc. 2007; 2(2):322-8. PMC: 3623971. DOI: 10.1038/nprot.2007.44. View

19.

Petit-Demouliere B, Chenu F, Bourin M . Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl). 2004; 177(3):245-55. DOI: 10.1007/s00213-004-2048-7. View

20.

Iyengar S, Webster A, Hemrick-Luecke S, Xu J, Simmons R . Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004; 311(2):576-84. DOI: 10.1124/jpet.104.070656. View